Relevant bibliographies by topics / Anti-metastatic

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Anti-metastatic'

Author: Grafiati
Published: 4 June 2021
Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-metastatic.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-metastatic"

1

PA, Steeg. "Nm23: an “anti-metastatic” gene." Advances in Anatomic Pathology 2, no. 1 (January 1995): 55. http://dx.doi.org/10.1097/00125480-199501000-00024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jiang, Y. L., and Z. P. Liu. "Natural Products as Anti-Invasive and Anti-Metastatic Agents." Current Medicinal Chemistry 18, no. 6 (February 1, 2011): 808–29. http://dx.doi.org/10.2174/092986711794927711.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hung, Wen-Chun. "Anti-metastatic Action of Non-steroidal Anti-inflammatory Drugs." Kaohsiung Journal of Medical Sciences 24, no. 8 (August 2008): 392–97. http://dx.doi.org/10.1016/s1607-551x(08)70162-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ferreira, Adilson Kleber, Vanessa Morais Freitas, Débora Levy, Jorge Luiz Mária Ruiz, Sergio Paulo Bydlowski, Rose Eli Grassi Rici, Otaviano Mendonça R. Filho, Gilberto Orivaldo Chierice, and Durvanei Augusto Maria. "Anti-Angiogenic and Anti-Metastatic Activity of Synthetic Phosphoethanolamine." PLoS ONE 8, no. 3 (March 14, 2013): e57937. http://dx.doi.org/10.1371/journal.pone.0057937.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lapis, K., J. Timár, K. Pál, L. Kopper, and A. Jeney. "Phenotype of metastatic cells as target for anti-metastatic interventions." European Journal of Cancer and Clinical Oncology 23, no. 11 (November 1987): 1773. http://dx.doi.org/10.1016/0277-5379(87)90627-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Beavis, Paul A., Nicole Milenkovski, John Stagg, Mark J. Smyth, and Phillip K. Darcy. "A2Ablockade enhances anti-metastatic immune responses." OncoImmunology 2, no. 12 (December 2013): e26705. http://dx.doi.org/10.4161/onci.26705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Stock, Anna-Maria, Gabriele Troost, Bernd Niggemann, Kurt Zanker, and Frank Entschladen. "Targets for Anti-metastatic Drug Development." Current Pharmaceutical Design 19, no. 28 (July 1, 2013): 5127–34. http://dx.doi.org/10.2174/1381612811319280011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Flemming, Alexandra. "Unleashing NK cell anti-metastatic activity." Nature Reviews Drug Discovery 13, no. 4 (April 2014): 257. http://dx.doi.org/10.1038/nrd4297.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vummidi, Balayeshwanth R., Faiza Noreen, Jawad Alzeer, Karin Moelling, and Nathan W. Luedtke. "Photodynamic Agents with Anti-metastatic Activities." ACS Chemical Biology 8, no. 8 (May 28, 2013): 1737–46. http://dx.doi.org/10.1021/cb400008t.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hennessy, C., JA Henry, FEB May, BR Westley, B. Angus, and TWJ Lennard. "Expression of anti-metastatic gene nm23." British Journal of Cancer 63, no. 6 (December 1991): 1024. http://dx.doi.org/10.1038/bjc.1991.223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anti-metastatic"

1

Migliozzi, Matthew. "Investigating the anti-metastatic activity of semaphorin-3F." Thesis, Boston University, 2013. https://hdl.handle.net/2144/12162.

Full text
Abstract:
Thesis (M.A.)--Boston University
Metastasis is the leading cause of cancer-related deaths. Although there are many factors that promote and facilitate invasive tumors—angiogenesis and lymphangiogenesis provide a means by which invasive tumor cells can spread to distant organs. Semaphorins (SEMAs) were originally discovered for their role in axon guidance during development, however, SEMAs are now known for their anti-metastatic potential. SEMA3F is a 95-kDA protein that induces both anti-angiogenic and anti-lymphangiogenic effects by binding its receptor, Neuropilin 2 (NRP2). SEMA3F-induced signaling via NRP2/plexinA1 complexes inhibits RhoA and results in f-actin depolymerization. SEMA3F may also inhibit angiogenic and lymphangiogenic signaling by competitive inhibition of VEGF-C and VEGF-A binding to NRP2. In this study we have purified SEMA3F protein for use in several in vitro and in vivo studies. Endothelial cell spheroids were unable to produce sprouts during an in vitro spheroid sprouting assay when treated with SEMA3F. In addition, treatment with SEMA3F induced f-actin depolymerization and cell collapse during in vitro endothelial cell collapse assays. A375SM human melanoma cells were injected in nude mice and treated with SEMA3F purified protein. The resultant tumors showed decreased intra- and peri-tumoral lymphatic and vascular densities. Tumors in SEMA3F treated mice were also found to be more necrotic than those of the control. In a second study, slow release osmotic pumps containing SEMA3F protein were implanted in Nrp2+/LacZ heterozygous mice prior to the injection of B16F10 mouse melanoma cells. These mice exhibited decreased tumor volumes indicating SEMA3F may inhibit tumorigenesis. These results indicate the potential of SEMA3F as an anti-metastatic/anti-tumorigenic therapeutic.
APA, Harvard, Vancouver, ISO, and other styles
2

Rowling, Emily. "Pre-clinical evaluation of novel anti-metastatic targets." Thesis, University of Manchester, 2014. https://www.research.manchester.ac.uk/portal/en/theses/preclinical-evaluation-of-novel-antimetastatic-targets(caa9ab41-c054-4559-b575-3fd8974005a7).html.

Full text
Abstract:
Background: Radiotherapy is used in the treatment of over 50% of cancer patients and bar surgery, is the most effective cancer intervention. However, in the clinic secondary malignancies have been observed following radiotherapy and in vitro increased cell migration and invasion have been seen following radiation. The Src/FAK signalling pathway is known to play an important role in the metastatic phenotype through its involvement in cell adhesion, migration and invasion and we have previously demonstrated that radiotherapy can activate this pathway along with the phosphoinositide 3-kinase (PI3K) pathway, also associated with tumour metastases and an aggressive phenotype. Using pharmacological inhibitors, we have investigated combination approaches to evaluate whether Src and PI3K targeting is beneficial in a radiotherapy context, especially focusing on metastatic phenotype. We wished to relate pathway activation to cellular phenotype and increase understanding of the metastatic cascade, the processes involved and the signalling pathways taking the lead. Method: Using thyroid carcinoma cell lines FTC133 and 8505c the effects of Src inhibition using AZD0530, FAK inhibition using FAKi and PI3K inhibition using GDC-0941 were studied. The effects of radiotherapy alone, and in combination with the above inhibitors, were also studied. In vitro MTT, apoptosis and clonogenic assays were used to assess cell proliferation and cell survival and scratch assays, cell adhesion and cell spreading assays were used to assess the effects of the drugs on metastatic characteristics. In vivo tumour growth, survival and ex vivo clonogenics were used to measure the effects of AZD0530 and GDC-0941. Western blotting, immunofluorescence and immunohistochemistry was used to observe the effects on pathway activation and protein localisation. Results: Src and FAK inhibition reduced metastatic characteristics of thyroid carcinoma cell lines in vitro such as cell spreading and migration. FAK inhibition showed a greater effect on cell survival by MTT, clonogenic and apoptosis. In the thyroid carcinoma cell lines radiotherapy enhanced the metastatic phenotype. This was seen by enhanced activation of the Src and PI3K pathways, increased migration and invasion in vitro and enhanced tumour metastasis in vivo. By combining Src inhibition with radiation a reduction in metastatic characteristics was observed and by combining PI3K inhibition with radiotherapy radiosensitivity could be improved. With the triple combination of Src and PI3K inhibition with radiotherapy a significant reduction in cell survival was demonstrated in vitro compared to radiation alone and either inhibitor combined with radiation, with a corresponding significant reduction in tumour growth being observed in vivo. With the combination of Src and PI3K inhibition significant reductions in metastatic characteristics were also observed both in vitro and in vivo seen by a reduction in cell migration and tumour metastasis. Finally combined inhibition of the Src and PI3K pathway reduced the radiation enhanced activation of several pathways in vivo including Src and PI3K.Conclusions: Together these results suggest that the Src and PI3K pathways play a role in radiation enhanced metastatic characteristics in thyroid carcinoma and through combined inhibition of the pathway the negative effects of radiation, enhanced migration and invasion, can be inhibited and the cells can be made more radiosensitive. Full characterisation of the pathways involved in radiation induced motility and radioresistance will provide further rationale for combination therapies and provide potential for application of these therapies in the clinic.
APA, Harvard, Vancouver, ISO, and other styles
3

Dyer, Hayder. "Development of and its peptide derivatives as potential anti-angiogenic and anti-metastatic." Thesis, Queen's University Belfast, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.534745.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Menhofer, Magdalena H. "Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent." Diss., Ludwig-Maximilians-Universität München, 2014. http://nbn-resolving.de/urn:nbn:de:bvb:19-167962.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sharma, Ankur. "Development of nanoparticulate drug delivery systems for anti-metastatic Ran GTPase therapeutics." Thesis, Ulster University, 2017. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.725342.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sawan, Ali Sadek. "Tumour suppressor and anti-metastatic gene expression in human breast cancer : an immunohistochemical study." Thesis, University of Newcastle Upon Tyne, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.239797.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schmitt, Florian [Verfasser], and Rainer [Akademischer Betreuer] Schobert. "New Microtubule-destabilizing Agents : Optimization of their Anti-angiogenic, Vascular-disruptive, and Anti-metastatic Activity / Florian Schmitt ; Betreuer: Rainer Schobert." Bayreuth : Universität Bayreuth, 2018. http://d-nb.info/1178526321/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Menhofer, Magdalena H. [Verfasser], and Stefan [Akademischer Betreuer] Zahler. "Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent / Magdalena H. Menhofer. Betreuer: Stefan Zahler." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2014. http://d-nb.info/1049647912/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kubisch, Rebekka. "Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug." Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-158654.

Full text
Abstract:
In the present study the mechanisms leading to acquired chemoresistance, as well as new treatment strategies implying the prevention evading of tumor cells were addressed. Resistance formation is one of the major hurdles in cancer therapy. Metronomic antiangiogenic treatment of xenografted prostate cancer tumors in mice with cyclophosphamide (CPA) results in the appearance of resistant tumors. To investigate the complex molecular changes occurring during resistance formation, a comprehensive gene expression analysis of the resistant tumors in vivo was performed. A multitude of differentially expressed genes, e.g. PAS domain containing protein 1 (PASD1), annexin A3 (ANXA3), neurotensin (NTS) or plasminogen activator tissue (PLAT), were observed, when comparing resistant to in vivo passaged tumor samples. Moreover, tumor cells from in vivo and in vitro conditions showed a significant difference in target gene expression. For clarification of the mechanisms leading to the survival of tumor cells during maintained anti-angiogenic CPA therapy the differentially expressed genes were assigned to functional pathways like: axon guidance, steroid biosynthesis and complement and coagulation cascades. As blood flow might play a crucial role during maintained anti-angiogenic therapy, further analysis was focused on the genes grouped in complement and coagulation cascades. pregulation of anti-coagulatory ANXA3 and PLAT and downregulation of SERPIN A1 and other SERPIN-family members was shown by qPCR analysis. In contrast coagulation factor F3 was upregulated, accompanied by the expression of an altered gene product. Taken together, a potential role of anticoagulation as a resistance mechanism for anti-angiogenic CPA therapy could be described. Furthermore, the role of archazolid, a novel myxobacterial V-ATPase inhibitor in cancer treatment and in particular its action on the secreted cellular proteome was evaluated. As extracellular protein secretion may have an impact on invasive properties of tumor cells, the changes of the secretome profile of highly migratory urinary bladder carcinoma cells upon archazolid treatment were analyzed. An induced secretion of prometastatic lysosomal proteins such as the cathepsin family was observed. Interestingly, intracellular cathepsin B activity however strongly decreases and mature cathepsin B protein diminishes. It could be shown that archazolid inhibits the mannose-6-phosphate receptor mediated trafficking of procathepsin B from the trans-Golgi network to prelysosomal compartments, leading to an impaired cathepsin B maturation process. This results in an unnatural secretion of the inactive proenzyme and a dramatic decrease in intracellular cathepsin B activity. Importantly, also in vivo an archazolid induced reduction of cathepsin B activity was proven and archazolid treatment resulted in a reduced formation of distant metastases in the lungs. In summary these results indicate that archazolid in addition to its known anti-migratory properties might exert an anti-metastatic effect by reducing the activity of pro metastatic proteases like cathepsin B.
APA, Harvard, Vancouver, ISO, and other styles
10

Stoiber, Katharina [Verfasser], and Angelika [Akademischer Betreuer] Vollmar. "The myxobacterial acetyl-CoA carboxylase inhibitor Soraphen A as a novel anti-metastatic and anti-proliferative agent / Katharina Stoiber ; Betreuer: Angelika Vollmar." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2016. http://d-nb.info/1127528025/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Anti-metastatic"

1

Calabrò, Fabio, and Cora N. Sternberg. Treatment of metastatic bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Full text
Abstract:
Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.
APA, Harvard, Vancouver, ISO, and other styles
2

Wong, Han Hsi, Basma Greef, and Tim Eisen. Treatment of metastatic renal cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0089.

Full text
Abstract:
Metastatic renal cancer is resistant to standard chemotherapy. Although some patients with indolent disease can be initially managed with observation, the majority of patients will require aggressive treatment soon after diagnosis. Options include cytoreductive nephrectomy, resection of a solitary metastasis in highly selected cases, or systemic therapy options. The TKIs sunitinib and pazopanib are currently the first-line treatments of choice. Whilst axitinib and cabozantinib have important roles in the second line the PD-1 checkpoint inhibitor, nivolumab, is now established as standard second line therapy. Inhibitors of the mammalian target of rapamycin (mTOR) pathway, everolimus and temsirolimus, interleukin-2 as well as the anti-angiogenic antibody bevacizumab have also been shown to be effective. The treatment paradigm of metastatic renal cancer is constantly changing as evidence from clinical trials continues to emerge. With the development of agents addressing novel targets such as T-cell regulation, the future certainly looks brighter for patients diagnosed with this disease.
APA, Harvard, Vancouver, ISO, and other styles
3

Hodgkiss, Andrew. Psychiatric consequences of particular cancers. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0004.

Full text
Abstract:
Certain tumour types can cause psychopathology through direct biological mechanisms such as metastatic spread to the brain, release of onconeuronal antibodies, ectopic hormone secretion, or release of pro-inflammatory cytokines. Lung cancers, adenocarcinoma of the pancreas, brain tumours, and ovarian tumours are considered in detail. Confusional states due to brain metastases, syndrome of inappropriate ADH secretion, hypercalcaemia of malignancy, and anti-Hu encephalitis are found in lung cancers. Severe depression, due to interleukin-6 release and its actions on the HPA axis and tryptophan metabolism, is common in adenocarcinoma of the pancreas. Anti-NMDA-receptor limbic encephalitis, clinically indistinguishable from acute schizophrenia, can complicate teratomas. Gliomas, pituitary tumours, and thyroid, adrenal, and testicular tumours can also disrupt mental health through various biological mechanisms described here.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Anti-metastatic"

1

Das, Millie, and Heather Wakelee. "Anti-Angiogenic Agents in Metastatic NSCLC." In Lung Cancer, 527–40. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gandalovičová, Aneta, Daniel Rosel, and Jan Brábek. "Migrastatics – Anti-metastatic Drugs Targeting Cancer Cell Invasion." In Approaching Complex Diseases, 203–11. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-32857-3_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zander, Thomas, Valentin Goede, and Michael Hallek. "Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy." In Tumor Angiogenesis, 1–16. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-31215-6_16-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zander, Thomas, Valentin Goede, and Michael Hallek. "Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy." In Tumor Angiogenesis, 379–94. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-33673-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Martins, Marta, André Mansinho, Raquel Cruz-Duarte, Soraia Lobo Martins, and Luís Costa. "Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All." In Targeted Therapy of Colorectal Cancer Subtypes, 113–31. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02771-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ayodele, Olubukola, and Lillian L. Siu. "New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer." In Critical Issues in Head and Neck Oncology, 337–52. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_23.

Full text
Abstract:
AbstractChemotherapy has been the backbone for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RMNPC), which remains an incurable disease. Currently the most active area of therapeutic investigations in RMNPC is in immunotherapy, especially after the results of five anti-programmed death-1 (anti-PD-1) antibodies, i.e. pembrolizumab, nivolumab, camrelizumab, toripalimab and tislelizumab, have demonstrated monotherapy objective response rates of 21%–43%. Combinations using anti-PD1/L1 antibodies as backbone to evaluate their additivity or synergy with cytotoxic chemotherapy, molecularly targeted agents, or other immuno-oncology compounds are actively being developed. Besides immune checkpoint blockade, additional ways to modulate the host immune system, such as Epstein-Barr virus (EBV)-directed vaccination against viral antigens (such as EBNA1, LMP1, LMP2) with dendritic cells or peptides, adoptive cell transfer of autologous or HLA-matched allogeneic EBV-specific cytotoxic T lymphocytes, CAR or TCR T-cell therapy, personalized cancer vaccines and oncolytic viruses are being explored. Finally, novel molecularly targeted agents that have entered human testing in RMNPC include apatinib and anlotinib (antiangiogenic agents), MAK683 (an embryonic ectoderm development or EED protein inhibitor), among others. This review provides an update of ongoing clinical trials evaluating these new compounds in RMNPC.
APA, Harvard, Vancouver, ISO, and other styles
7

Saridaki, Zacharenia, and John Souglakos. "Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer." In Resistance to Targeted Anti-Cancer Therapeutics, 125–41. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7654-2_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schirrmacher, V. "Successful Application of a Virus-Modified Tumor Vaccine for Anti-Metastatic Cancer Immunotherapy." In Human Malignancies, 132–42. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73642-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Harrington, Kevin J. "Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer?" In Critical Issues in Head and Neck Oncology, 205–19. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_14.

Full text
Abstract:
AbstractDespite significant technical improvements in the management of patients with locoregionally-advanced head and neck cancers, too many patients fail to achieve durable remissions that ultimately translate into cures. Loco-regional recurrence and/or metastatic relapse after intensive local therapies remain the scourge of those who suffer from this disease, and the surgeons and physicians who treat them. Regrettably, until now, we have failed to develop effective adjuvant therapies that can be delivered after the completion of definitive loco-regional treatment in order to reduce the risk of disease relapse. In this chapter, approaches based on cytotoxic chemotherapy, targeted therapies directed against c-erbB/HER receptors and immune checkpoint inhibition will be discussed. Neither cytotoxic chemotherapy nor anti-HER-family targeted therapies have proven to be successful as adjuvant therapies for locoregionally-advanced head and neck cancers, but there is significant hope that anti-PD1/anti-PD-L1-targeted antibody therapies may deliver progress in this area for the first time.
APA, Harvard, Vancouver, ISO, and other styles
10

Hollander, Nurit. "The Immunotherapeutic Effect of Anti Lyt-1 Antibodies on Local and Metastatic Tumor Growth." In Microenvironments in the Lymphoid System, 819–26. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2463-8_99.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti-metastatic"

1

Zhang, Lei, Chengyu Wu, Ming Zhao, Yong Zhang, and Robert M. Hoffman. "Abstract 2804: Anti-tumor and anti-metastatic efficacy of TCM on prostate cancer in orthotopic model of metastatic cancer." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2804.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, CL, JC Yang, CY Peng, and YC Wu. "Anti-metastatic and anti-allergic spirostanol saponins from Solanum macaonense and S. torvum." In GA 2017 – Book of Abstracts. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1608067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Granot, Zvi, Erik Henke, Elizabeth A. Comen, Tari A. King, Larry Norton, and Robert Benezra. "Abstract 1415: Anti-metastatic properties of tumor-entrained neutrophils." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1415.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Adelaiye-Ogala, Remi M., Li Shen, Sreenivasulu Chintala, Eric Ciamporcero, Ashley Orillion, May Elbanna, Shengyu Ku, et al. "Abstract 4132: Anti-tumor and anti-metastatic effect of sunitinib in a patient derived metastatic clear cell renal cell carcinoma xenograft model." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Karki, Namrata, Frank Greenway, William Hansel, Sita Aggarwal, and Jack N. Losso. "Abstract 4128: Anti-angiogenic and anti-metastatic activities of juglone in pancreatic cancer cells." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4128.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Katner, Samantha J., Erica Peterson J. Peterson, Eriko Katsuta, Stephanie C. DeMasi, Jennifer Koblinski, Kazuaki Takabe, and Nicholas P. Farrell. "Abstract 17: Anti-metastatic platinum through glycan targeting in breast cancer." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hawkins, Gabrielle M., Sarah E. Paraghamian, Yali Fan, Wenchaun Sun, Xin Zhang, Varun Prabhu, Joshua E. Allen, Chunxiao Zhou, and Victoria L. Bae-Jump. "Abstract 5336: Olaparib potentiates the anti-proliferative and anti-metastatic effects of ONC206 in ovarian cancer cells." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5336.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rivera-Robles, Michael John, Julia Medina-Velázquez, Gabriela M. Asencio-Torres, Sahily González-Crespo, Brian C. Rymond, José Rodríguez-Medina, and Suranganie Dharmawardhane. "Abstract 3994: Anti-metastatic drug MBQ-167 regulates cell polarity via Cdc42." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fridlender, ZG, V. Kapoor, J. Sun, G. Cheng, L. Snyder, and SM Albelda. "Anti-CCL2 Antibodies Decrease Spontaneous Metastatic Disease in a Model of NSCLC." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5131.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Alkahlout, Amal Shahada, Ali Eid, Ipek Goktepe, and Alaeldin Saleh. "Anti-proliferative and Anti-metastatic Effect of Aqueous Extract of Origanum Syriacum on Aggressive Human Breast Cancer Cells." In Qatar Foundation Annual Research Conference Proceedings. Hamad bin Khalifa University Press (HBKU Press), 2016. http://dx.doi.org/10.5339/qfarc.2016.hbsp2124.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Anti-metastatic"

1

Ruoslahti, Erkki I. New Anti-Metastatic and Anti-Angiogenic Compound for Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2001. http://dx.doi.org/10.21236/ada406191.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rouslahti, Erkki I. New Anti-Metastatic and Anti-Angiogenic Compound for Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2003. http://dx.doi.org/10.21236/ada420794.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Peters, David. Targeting of an Anti-Metastatic and Anti-Angiogenic Compound to Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, June 2005. http://dx.doi.org/10.21236/ada443687.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Akerman, Maria. Targeting of an Anti-Metastatic and Anti-Angiogenic Compound to Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, June 2003. http://dx.doi.org/10.21236/ada417959.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Akerman, Maria. Targeting of an Anti-Metastatic and Anti-Angiogenic Compound to Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, June 2004. http://dx.doi.org/10.21236/ada427128.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhang, Xiaohui, Yidong Zhou, Feng Mao, Yan Lin, Songjie Shen, and Qiang Sun. Efficacy and Safety of Anti-HER2 Agents in Combination with Chemotherapy for Metastatic HER2-positive Breast Cancer Patient: A Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anti-metastatic' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography